Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Star Scientific IND Blocks Supplement Marketing Options – FDA

This article was originally published in The Tan Sheet

Executive Summary

An FDA warning letter deems Star Scientific’s CigRx and Anatabloc supplements unapproved drugs due to multiple issues, including claims. The firm’s approved IND study for the ingredient also prevents its use in supplements, the agency says.

You may also be interested in...



Industry News Roundup

MediNatura buys Heel Group USA; FDA refuses to file Rock Creek Pharmaceuticals NDI notification; FTC bans businessman from weight-loss industry; AHPA recommends cannabis quality-control regulations; new leadership team at NBTY; FDA cites supplement inflammation claims; and Green Cures signs marketing partners.

Industry News Roundup

MediNatura buys Heel Group USA; FDA refuses to file Rock Creek Pharmaceuticals NDI notification; FTC bans businessman from weight-loss industry; AHPA recommends cannabis quality-control regulations; new leadership team at NBTY; FDA cites supplement inflammation claims; and Green Cures signs marketing partners.

Between A Rock Creek And A Hard Place: Firm Stops Supplement Sales, Weathers Litigation

Rock Creek Pharmaceuticals faces investor and consumer class-action complaints on top of ending sales of its nutritionals following an FDA warning. Moreover, the company name is known more in connection with federal officials’ investigation of the former governor of Virginia than for its products.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS106777

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel